Study Summary
This is a Phase 1/2, first-in-human, open-label, dose-escalating and expansion trial designed to assess the safety and efficacy of VNX-202 in patients with HER2 positive cancers.
Interested in this trial?
Submit an InquiryInterventions
Dose Level 1, VNX-202GENETIC
Adeno-associated viral vector encoding the CD3/HER2 Bi-Specific T-Cell Engager (AAV.CD3/HER2), Single IV Infusion
Dose Level 2, VNX-202GENETIC
Adeno-associated viral vector encoding the CD3/HER2 Bi-Specific T-Cell Engager (AAV.CD3/HER2), Single IV Infusion
Dose Level 3, VNX-202GENETIC
Adeno-associated viral vector encoding the CD3/HER2 Bi-Specific T-Cell Engager (AAV.CD3/HER2), Single IV Infusion
Dose Level 4, VNX-202GENETIC
Adeno-associated viral vector encoding the CD3/HER2 Bi-Specific T-Cell Engager (AAV.CD3/HER2), Single IV Infusion
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Valkyrie Clinical Trials | Los Angeles | California | United States |
| SCRI Denver DDU at HealthOne | Denver | Colorado | United States |
| Memorial Sloan Kettering Cancer Center | New York | New York | United States |
| Thomas Jefferson University, Sidney Kimmel Cancer Center | Philadelphia | Pennsylvania | United States |
| SCRI Oncology Partners | Nashville | Tennessee | United States |
| UT MD Anderson Cancer Center | Houston | Texas | United States |